Mukul Agarwal
Corporate Officer/Principal at FORTY SEVEN, INC.
Profile
Mukul Agarwal is Vice President-Corporate Development of Forty Seven, Inc.
Mr. Agarwal previously held the position of Vice President-Business Development of Revance Therapeutics, Inc. and Senior Director-Corporate Development & Strategy at Anacor Pharmaceuticals, Inc.
Mr. Agarwal received an MBA from Carnegie Mellon University, a graduate degree from The Ohio State University and an undergraduate degree from Indian Institute of Technology New Delhi.
Mukul Agarwal active positions
Companies | Position | Start |
---|---|---|
FORTY SEVEN, INC. | Corporate Officer/Principal | - |
Former positions of Mukul Agarwal
Companies | Position | End |
---|---|---|
REVANCE THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-02-28 |
ANACOR PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Training of Mukul Agarwal
Carnegie Mellon University | Masters Business Admin |
The Ohio State University | Graduate Degree |
Indian Institute of Technology New Delhi | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
REVANCE THERAPEUTICS, INC. | Health Technology |
Private companies | 2 |
---|---|
Anacor Pharmaceuticals LLC
Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Forty Seven, Inc.
Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |